This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IMMNOV BTA Stock Overview

A diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. More details

IMMNOV BTA fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 96.7% below our estimate of its fair value

Earnings are forecast to grow 94.89% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (SEK1M)

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Immunovia AB (publ) Competitors

Acarix

OM:ACARIX

SEK 263.3m

IRRAS

OM:IRRAS

SEK 181.7m

SciBase Holding

OM:SCIB

SEK 94.0m

Medclair

NGM:MCLR

SEK 113.8m

Price History & Performance

Summary of share price highs, lows and changes for Immunovia
Historical stock prices
Current Share Price	SEK 4.08
52 Week High	SEK 6.80
52 Week Low	SEK 3.90
Beta	1.37
1 Month Change	-40.00%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-40.00%

Recent updates

Shareholder Returns

	IMMNOV BTA	SE Medical Equipment	SE Market
7D	-0.2%	0.4%	0.7%
1Y	n/a	-9.4%	6.3%

Return vs Industry: Insufficient data to determine how IMMNOV BTA performed against the Swedish Medical Equipment industry.

Return vs Market: Insufficient data to determine how IMMNOV BTA performed against the Swedish Market.

Price Volatility

Is IMMNOV BTA's price volatile compared to industry and market?
IMMNOV BTA volatility
IMMNOV BTA Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.5%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: IMMNOV BTA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine IMMNOV BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	64	Jeff Borcherding	www.immunovia.com

Immunovia AB (publ), a diagnostic company, develops and commercializes blood-based diagnostics for cancer in Sweden and internationally. It offers IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

Immunovia AB (publ) Fundamentals Summary

How do Immunovia's earnings and revenue compare to its market cap?
IMMNOV BTA fundamental statistics
Market cap	SEK 193.60m
Earnings (TTM)	-SEK 168.09m
Revenue (TTM)	SEK 1.15m

169.1x

P/S Ratio

-1.2x

P/E Ratio

Is IMMNOV BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMMNOV BTA income statement (TTM)
Revenue	SEK 1.15m
Cost of Revenue	SEK 4.21m
Gross Profit	-SEK 3.07m
Other Expenses	SEK 165.03m
Earnings	-SEK 168.09m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

May 23, 2023

Earnings per share (EPS)	-3.71
Gross Margin	-267.77%
Net Profit Margin	-14,680.52%
Debt/Equity Ratio	0%

How did IMMNOV BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/05/07 03:51
End of Day Share Price	2023/05/04 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunovia AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Lars Hevreng	Danske Bank
Juan Pedro Rodríguez Serrate	Edison Investment Research
Alexandru Cogut	Kempen & Co. NV

Immunovia OM:IMMNOV BTA Stock Report